Soluble B7-H3 in Colorectal Cancer

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Colorectal cancer (CRC) remains a significant global health challenge.
• Immunity checkpoints, such as B7-H3, play a crucial role in cancer immune evasion.
• Understanding biomarkers for CRC progression is vital for improved diagnostics and prognostics.

Purpose of the Study:

• To investigate the concentration of soluble B7-H3 (sB7-H3) in the serum of colorectal cancer patients.
• To compare sB7-H3 levels between CRC patients at various stages and healthy controls.
• To explore the association between sB7-H3 levels and tumor progression in CRC.

Main Methods:

• Comparative ELISA was utilized to quantify serum sB7-H3 levels.
• Statistical analysis, including ROC analysis, was performed to assess diagnostic potential.
• Correlation analysis was conducted to link sB7-H3 levels with tumor stage and metastasis.

Main Results:

• CRC patients exhibited significantly higher median serum sB7-H3 levels (19.66 ng/ml) compared to healthy donors (16.76 ng/ml) (p=0.0025).
• ROC analysis indicated a sensitivity of 62.9% and specificity of 56.7% for CRC detection at a cut-off of 17.62 ng/ml (p=0.0028).
• sB7-H3 levels were significantly lower in patients with regional metastases (p=0.039) and tended to decrease in later disease stages.

Conclusions:

• Elevated serum sB7-H3 levels may serve as a potential biomarker for colorectal cancer.
• Decreased sB7-H3 levels are associated with tumor progression and metastasis in CRC.
• Higher serum sB7-H3 concentration could indicate a favorable prognosis in colorectal cancer patients.